Gout--what are the treatment options?

Area of Science:

• Rheumatology
• Internal Medicine
• Pharmacology

Background:

• Gout incidence and prevalence have increased significantly.
• Current treatment often focuses on acute attacks, neglecting long-term urate reduction.
• Inadequate management can lead to disease progression and crystal deposition.

Purpose of the Study:

• To differentiate between acute gout attack treatment and long-term serum urate (SU) lowering.
• To emphasize the necessity of sustained SU reduction for uric acid crystal dissolution.
• To review current and emerging therapeutic strategies for comprehensive gout management.

Main Methods:

• Review of existing literature on gout treatment modalities.
• Analysis of pharmacological options for acute inflammation and chronic SU lowering.
• Discussion of treatment goals, including SU levels below saturation threshold.

Main Results:

• Acute gout treatment options include NSAIDs, colchicine, and corticosteroids, with prompt initiation and appropriate dosing being key.
• Long-term SU-lowering therapy is crucial for dissolving urate crystals and preventing flares.
• Allopurinol, benzbromarone, febuxostat, and pegloticase are primary agents for SU reduction, with others used adjunctively.

Conclusions:

• Comprehensive gout management necessitates both acute attack treatment and long-term SU-lowering strategies.
• Achieving and maintaining SU levels below 6.0 mg/dL is essential for disease control.
• Recent therapeutic advancements offer new hope for patients refractory or intolerant to existing treatments.